Eli Lilly’s Retatrutide Shows Weight Loss in Diabetes Trial

Eli Lilly’s experimental drug retatrutide has enabled adults living with type 2 diabetes and obesity to achieve substantial weight loss while significantly improving blood sugar control and cardiometabolic health, according to final results from an 80-week global phase 3 clinical trial reported in 2026. The landmark findings, published in The Lancet and presented at the European Association for the Study of Diabetes, mark a major step forward for patients with diabetes, a population where weight-loss interventions have historically proved more challenging.

The TRIUMPH-2 Trial Design and Core Findings

The global TRIUMPH-2 trial enrolled 2,047 adults with obesity or overweight alongside a diagnosis of type 2 diabetes across eight countries. Participants were randomized to receive weekly subcutaneous doses of retatrutide-administered at 4 mg, 9 mg, or 12 mg-or a matching placebo, alongside structured lifestyle counseling.

By the conclusion of the 80-week study period, individuals assigned to the highest 12 mg dose lost an average of 18.8% of their starting body weight, compared to an average of just 5.1% in the placebo group. In specific subgroups and extended analyses, some patients achieved reductions of up to 23%, translating to losses of roughly 60 pounds. Additionally, nearly 60% of participants on the highest dose lowered their body mass index (BMI) enough to no longer meet clinical obesity criteria.

Blood Sugar Control and Metabolic Improvements

Beyond shedding body mass, participants experienced profound improvements in glycemic management. Patients taking the 12 mg dose reduced their average HbA1c levels by up to 1.6%. Approximately 40% to 63% of participants on the highest regimen successfully achieved blood sugar levels below the standard diabetes threshold of 6.5% while simultaneously losing at least 10% of their total body weight.

Researchers also noted broad enhancements in associated cardiometabolic health indicators, including reductions in systolic blood pressure, triglycerides, and low-density lipoprotein (LDL) cholesterol. More than a third of trial participants entered the study with prediabetes, a condition that reportedly resolved in the vast majority of those individuals by the study’s end.

How Retatrutide Works: The Triple-Target Mechanism

Often dubbed a “triple-G” receptor agonist, retatrutide functions via a novel single synthetic peptide designed to stimulate three distinct gut hormone receptors simultaneously:

• GLP-1 (Glucagon-like peptide-1): Stimulates insulin release in response to food, slows gastric emptying, and acts on the brain to signal satiety and curb appetite.
• GIP (Glucose-dependent insulinotropic polypeptide): Promotes insulin secretion, triggers lipid degradation in fat tissues, and works synergistically to regulate energy balance.
• Glucagon: Raises energy expenditure and helps control blood sugar and lipid profiles, a hormone unique to retatrutide compared to existing dual or single-agonist medications.

This combined hormonal approach yields more potent downstream metabolic activity than medications targeting only GLP-1 (such as Wegovy or Ozempic) or both GLP-1 and GIP (such as Zepbound or Mounjaro).

Safety Profile and Side Effects

The safety and tolerability profile observed in the retatrutide diabetes trial remained consistent with other therapies incorporating GLP-1 receptor agonists. The most frequent adverse events were transient, mild-to-moderate gastrointestinal symptoms.

• Nausea: Reported by roughly 14% to 28% of participants across active dose groups.
• Diarrhea: Observed in 27% to 34% of treated patients.
• Vomiting and Constipation: Incremental increases were noted as dose escalations progressed.

Eli Lilly has indicated plans to submit a formal application seeking U.S. Food and Drug Administration (FDA) approval for retatrutide in early 2027.

Frequently Asked Questions About Retatrutide

What is retatrutide and how does it work?

Retatrutide is an experimental once-weekly injectable peptide developed by Eli Lilly. It acts as a triple hormone receptor agonist, targeting GLP-1, GIP, and glucagon receptors to regulate appetite, enhance metabolism, and control blood sugar.

How much weight did participants lose in the diabetes trial?

In the 80-week TRIUMPH-2 phase 3 trial for adults with type 2 diabetes and obesity, participants on the highest 12 mg dose lost an average of 18.8% of their starting body weight, with some losing up to 23% (roughly 60 pounds).

How does retatrutide differ from Ozempic, Wegovy, or Zepbound?

While Ozempic and Wegovy (semaglutide) target only GLP-1, and Zepbound and Mounjaro (tirzepatide) target GLP-1 and GIP, retatrutide uniquely incorporates a third hormone component-glucagon-to further increase energy expenditure and metabolic activity.

What are the common side effects of retatrutide?

The most common side effects are gastrointestinal in nature, including nausea, diarrhea, vomiting, and constipation, which are generally mild to moderate and similar to those seen with other advanced metabolic medications.

When will retatrutide be available to the public?

Eli Lilly has announced plans to submit a regulatory approval request for retatrutide to the U.S. FDA in early 2027. Market availability will depend on subsequent regulatory review and approval timelines.